Novacea, a developer of an analog of Vitamin D to treat prostate cancer, reduced its offering price to $6.50 from a range of $11 to $13. Bear Stearns and Cowen & Co. are the lead underwriters on the deal. Timing for the deal is day-to-day.
Novacea, a developer of an analog of Vitamin D to treat prostate cancer, reduced its offering price to $6.50 from a range of $11 to $13. Bear Stearns and Cowen & Co. are the lead underwriters on the deal. Timing for the deal is day-to-day.